Search
Now showing items 1-4 of 4
Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
(
Bentham Science Publishers
, 2017 , Article)
Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes mellitus and the leading cause of end stage renal disease. One of the key pathways activated in DN is the polyol pathway, in which ...
Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury
(
Hindawi
, 2017 , Article)
Diabetic nephropathy (DN) is the leading cause of end stage renal disease worldwide. Increased glucose flux into the aldose reductase (AR) pathway during diabetes was reported to exert deleterious effects on the kidney. ...
Corrigendum: Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury (BioMed Research International (2017) 2017 (5903105) DOI: 10.1155/2017/5903105)
(
Hindawi Limited
, 2019 , Other)
Following publication of the article, Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury, the authors were made aware that the effects of epalrestat on the high ...
Comparison Of In Vitro Models Of Diabetic Nephropathy Using Renal Tubular Cells
(
Hamad bin Khalifa University Press (HBKU Press)
, 2014 , Conference Paper)
Background: Diabetic nephropathy (DN) is a chronic and serious complication associated with diabetes. The standardization of an in vitro model to best represent DN is very challenging due to the chronic nature of the ...